BRIEF-AbbVie Files FDA, EMA Applications For Rinvoq (Upadacitinib) For Adults, Teens With Vitiligo

Reuters
Feb 03
BRIEF-AbbVie Files FDA, EMA Applications For Rinvoq (Upadacitinib) For Adults, Teens With Vitiligo

Feb 3 (Reuters) - Abbvie Inc ABBV.N:

  • ABBVIE SUBMITS REGULATORY APPLICATIONS TO FDA AND EMA FOR UPADACITINIB (RINVOQ®) IN ADULTS AND ADOLESCENTS WITH VITILIGO

Source text: ID:nPn8D2BXla

Further company coverage: ABBV.N

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10